Advertisement

European Journal of Dermatology

, Volume 27, Issue 4, pp 369–374 | Cite as

Cutaneous Kaposi sarcoma during treatment with superpotent topical steroids and methotrexate for bullous pemphigoid: three cases

  • Raphaëlle Binois
  • Marion Nadal
  • Eric Esteve
  • Anne De Muret
  • Rémy Kerdraon
  • Tarik Gheit
  • Massimo Tommasino
  • Pauline Gaboriaud
  • Antoine Touze
  • Mahtab Samimi
Clinical report

Abstract

Background

Iatrogenic Kaposi sarcoma (KS) has previously been reported in patients with bullous pemphigoid (BP), in relation to systemic steroids.

Objectives

To report three cases of previously unreported cutaneous KS during treatment with superpotent topical steroids (STS) and methotrexate (MTX).

Patients and Methods

All patients were elderly men with BP treated with STS for 2 to 32 months (cumulative doses: 2,700-9,150 g) beforeMTXwas introduced (dosage: 10-12.5 mg/week).

Results

KS occurred one to nine months after the combined therapy. In one case, KS rapidly resolved after withdrawal of MTX. In two cases, vinblastine and/or radiotherapy were required to achieve regression of KS. Human herpes virus 8 (HHV8) latency-associated nuclear antigen was not expressed in BP lesions biopsied prior to development of KS (n = 3), but HHV8 DNA was detected in BP lesions from the patient with the most aggressive KS.

Conclusion

Several predisposing factors were identified, including sex and age, high cumulative doses of STS, combination with MTX, and impaired immune status. In such cases, serum antibodies against HHV8 infection may be investigated in BP patients before introduction of MTX in order to guide clinical monitoring.

Key words

bullous pemphigoid human herpes virus 8 Kaposi sarcoma methotrexate topical steroids 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Guillet G, Chouvet B, Thivolet J, Perrot H. Immunosuppressive therapy and Kaposi’s sarcoma: two case reports. Ann Dermatol Venereol 1980; 107: 907–19.PubMedGoogle Scholar
  2. 2.
    Halpern SM, Parslew R, Cerio R, Kirby JT, Sharpe GR. Kaposi’s sarcoma associated with immunosuppression for bullous pemphigoid. Br J Dermatol 1997; 137: 140–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Xiao T, Lu H-G, Jin G-Y, et al. Immunosuppressive Kaposi’s sarcoma with bullous pemphigoid associated with hepatitis B virus infection. Eur J Dermatol 2009; 19: 403–4.PubMedGoogle Scholar
  4. 4.
    Tye MJ. Bullous pemphigoid and Kaposi’s sarcoma. Arch Dermatol 1970; 101: 690–1.CrossRefPubMedGoogle Scholar
  5. 5.
    Scaparro E, Borghi S, Rebora A. Kaposi’s sarcoma after immunosuppressive therapy for bullous pemphigoid. Dermatologica 1984; 169: 156–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Trofimova IB, Reznikova MM. A case of immunodependent Kaposi’s sarcoma against a background of glucocorticoid treatment. Vestn Dermatol Venerol 1989; 11: 69–70.Google Scholar
  7. 7.
    Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29: 391–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Sato-Matsumura KC, Matsumura T, Nabeshima M, Katano H, Sata T, Koizumi H. Serological and immunohistochemical detection of human herpesvirus 8 in Kaposi’s sarcoma after immunosuppressive therapy for bullous pemphigoid. Br J Dermatol 2001; 145: 633–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Stavrianeas NG, Katoulis AC, Kanelleas AI, et al. Kaposi’s sarcoma as a Köbner phenomenon in a patient with bullous pemphigoid and sarcoidosis. Clin Exp Dermatol 2007; 32: 579–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Boudhir H, Mael-Ainin M, Senouci K, Hassam B, Benzekri L. Kaposi’s disease: an unusual side-effect of topical corticosteroids. Ann Dermatol Venereol 2013; 140: 459–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Gaspari AA, Marchese S, Powell D, Rady PL, Tyring SK. Identification of HHV-8 DNA in the skin lesions of Kaposi’s sarcoma in an immunosuppressed patient with bullous pemphigoid. J Am Acad Dermatol 1997; 37: 843–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang T, Li C, Yang C, et al. Identification of human herpesvirus-8 in Kaposi’s sarcoma with bullous pemphigoid. Chin Med J 2014; 127: 786–8.PubMedGoogle Scholar
  13. 13.
    Kawada J, Iwata N, Kitagawa Y, Kimura H, Ito Y. Prospective monitoring of Epstein-Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab. Mod Rheumatol 2012; 22: 565–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang N, Wilkinson S, Riaz M, Östör AJ, Nisar MK. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol 2012; 30: 962–71.PubMedGoogle Scholar
  15. 15.
    Boulanger E1, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003; 73: 143–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Pérez E, Barnadas MA, García-Patos V, et al. Kaposi’s sarcoma in a patient with erythroblastopenia and thymoma: reactivation after topical corticosteroids. Dermatology 1998; 197: 264–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Memar OM, Rady PL, Goldblum RM, Yen A, Tyring SK. Human herpesvirus 8 DNA sequences in blistering skin from patients with pemphigus. Arch Dermatol 1997; 133: 1247–51.CrossRefPubMedGoogle Scholar
  18. 18.
    Galan A, Hui P, McNiff JM. Absence of human herpesvirus 8 in pemphigus and bullous pemphigoid. Int J Clin Exp Pathol 2009; 2: 456–62.PubMedPubMedCentralGoogle Scholar

Copyright information

© John Libbey Eurotext 2017

Authors and Affiliations

  • Raphaëlle Binois
    • 1
    • 2
  • Marion Nadal
    • 1
    • 3
  • Eric Esteve
    • 2
  • Anne De Muret
    • 4
  • Rémy Kerdraon
    • 5
  • Tarik Gheit
    • 6
  • Massimo Tommasino
    • 6
  • Pauline Gaboriaud
    • 7
  • Antoine Touze
    • 7
  • Mahtab Samimi
    • 1
    • 3
    • 7
  1. 1.Boulevard TonneléUniversity François RabelaisTours Cedex 9France
  2. 2.Department of DermatologyHospital of OrléansOrléansFrance
  3. 3.Department of DermatologyHospital of ToursTours Cedex 9France
  4. 4.Department of PathologyHospital of ToursTours Cedex 9France
  5. 5.Department of PathologyHospital of OrléansOrléansFrance
  6. 6.International Agency for Research on CancerInfections and Cancer Biology GroupLyon CEDEX 08France
  7. 7.Laboratory “Biologie des Infections à Polyomavirus”, ISP 1282INRA-University FrançoisRabelais, ToursFrance

Personalised recommendations